Ganetespib-based therapies suppress splenic expansion of activated T cells and abnormal plasma cells.

<p>(A) Plot shows the total number of splenocytes. Data are shown for 7–12 mice per treatment group. (*p<0.007; **p<0.0037; ***p<0.0012 versus vehicle-treated animals). (B) Splenocytes were isolated, counted and analyzed for the total number of CD3⁺CD4^-CD8^- T cells (<i>left panel</i>; *p<0.0001, **p<0.0004) or the number of mature phenotype CD3⁺CD4⁺ and CD3⁺CD8⁺ T lymphocytes (<i>right panel</i>; *p = 0.04, **p = 0.002). (C) Numbers of B220^-CD19^-CD38⁺CD138⁺ plasma cells (<i>left panel</i>; *p = 0.03, **p = 0.007, ***p = 0.004) and B220⁺CD19⁺ B cells (<i>right panel</i>).